Preferred Label : Trastuzumab;
NCIt synonyms : Trastuzumab Biosimilar CT-P6; rhuMAb HER2; Trastuzumab-dkst; Herceptin Trastuzumab Biosimilar PF-05280014; Herceptin Biosimilar PF-05280014; Trastuzumab Biosimilar ABP 980; Trastuzumab Biosimilar PF-05280014; Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup
c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain,
Dimer; Trastuzumab Biosimilar ALT02; Trastuzumab Biosimilar HLX02; trastuzumab biosimilar EG12014; Trastuzumab Biosimilar SB3; Trastuzumab Biosimilar SIBP-01; Trastuzumab Biosimilar QL1701;
NCIt related terms : Herceptin; Trastuzumab-anns; Trastuzumab-qyyp; Trastuzumab-pkrb; Trastuzumab-dttb;
NCIt definition : A recombinant humanized monoclonal antibody directed against the human epidermal growth
factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab
induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that
overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast
adenocarcinomas. (NCI04);
Alternative definition : NCI-GLOSS: A drug used alone or with other drugs to treat certain types of breast
cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive.
It is also being studied in the treatment of other types of cancer. Trastuzumab binds
to a protein called HER2, which is found on some cancer cells. This may help the immune
system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type
of HER2 receptor antagonist.;
UNII : P188ANX8CK;
CAS number : 180288-69-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 180288-69-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Herceptin; Ogivri; Herzuma; Trazimera; Ontruzant; Kanjinti; Biceltis; Hertraz; CANMab; Herclon;
Molecule name : ALT02; ABP 980; PF-05280014; RO0452317; SB3; QL-1701; QL 1701; CT-P6; CT-P06;
NSC code : 688097;
Codes from synonyms : CDR0000045439; CDR0000410745; 510; 512; 511; 48340; 48338; 48339;
Origin ID : C1647;
UMLS CUI : C0728747;
CISMeF manual mappings
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_analyseii_20090604.pdf
2009
Canada
drug information
trastuzumab
Trastuzumab
Adjuvant
Male Breast Carcinoma
breast cancer
Additive
Adjuvant Therapy Clinical Trial Setting
Childhood Breast Carcinoma
breast neoplasms
neoplasm, malignant
adjuvant, nos
Adjudicator
Trastuzumab
---
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_seinadjuvant_ad_et_rum_20070515.pdf
2007
Canada
drug information
Childhood Breast Carcinoma
neoplasm, malignant
Additive
trastuzumab
Trastuzumab
Adjuvant Therapy Clinical Trial Setting
adjuvant, nos
Trastuzumab
Male Breast Carcinoma
Adjuvant
breast cancer
Adjudicator
breast neoplasms
---
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_seinadjuvant_pgtm_20051004.pdf
2005
Canada
drug information
breast neoplasms
Childhood Breast Carcinoma
adjuvant, nos
Adjuvant Therapy Clinical Trial Setting
breast cancer
Adjuvant
neoplasm, malignant
trastuzumab
Trastuzumab
Trastuzumab
Adjudicator
Additive
Male Breast Carcinoma
---
